Seasoned Pharma and Biotech Executive to Support ALSA Portfolio Companies
London, 28 January 2025 –ALSA Ventures, a London-based life sciences venture capital firm dedicated to building and growing early-stage biotech companies developing transformative therapies, today announced the appointment of Bruce Goldsmith, PhD, as Operating Partner. Dr. Goldsmith brings over 25 years of pharmaceutical and biotechnology leadership experience to ALSA, having guided multiple companies from inception through clinical development and public offerings.
Dr. Goldsmith’s career spans senior positions at Johnson & Johnson, Allos Therapeutics, and Lycera Corp. He later joined Deerfield Healthcare as a Venture Partner, leading a new venture as CEO. Most recently, he served as CEO of Passage Bio, where he oversaw the company’s successful initial public offering and advanced four gene therapy programs to IND stage. Along the way, Dr. Goldsmith has led critical business development deals, driven corporate strategy, and managed operations at scale.
At ALSA Ventures, Dr. Goldsmith will play a vital role in helping create and operationalize ALSA portfolio companies. This special blend of scientific expertise and commercial experience will play an important role in realizing ALSA’s mission of delivering next generation therapeutics to address high unmet medical needs.
“We are delighted to welcome Bruce to ALSA Ventures,” said Alek Safarian, CEO of ALSA Ventures. “His track record in building successful biotech organizations, securing strategic partnerships, and leading multiple programs from idea to clinic perfectly complements our hands-on approach to company creation and growth. We look forward to leveraging his insights and experience to further strengthen our portfolio and pipeline.”
“I am excited to join ALSA Ventures during this important time of innovation in life sciences,” said Dr. Goldsmith. “ALSA’s commitment to supporting visionary founders and scientists, coupled with its focused approach to building companies around compelling biology, is exactly the environment where I can add the most value. I look forward to collaborating with the ALSA team and our portfolio companies to bring life-changing therapies to patients in need.”
About ALSA Ventures
ALSA Ventures is a London-based venture capital firm investing in early-stage biotech companies developing the next generation of therapeutics. Founded by a team of experienced entrepreneurs, scientists, and investors, ALSA Ventures takes a hands-on approach to building and growing companies around pioneering science, with the aim of delivering transformative therapies to patients with high unmet medical needs. Working closely with portfolio companies, ALSA provides strategic guidance, operational expertise, and access to a global network of industry partners.
